1. Home
  2. API vs TENX Comparison

API vs TENX Comparison

Compare API & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Agora Inc.

API

Agora Inc.

HOLD

Current Price

$4.09

Market Cap

339.0M

Sector

Technology

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$13.82

Market Cap

317.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
API
TENX
Founded
2013
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
339.0M
317.8M
IPO Year
2020
2001

Fundamental Metrics

Financial Performance
Metric
API
TENX
Price
$4.09
$13.82
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
266.3K
1.4M
Earning Date
05-26-2026
05-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$13.46
N/A
Revenue Next Year
$12.87
N/A
P/E Ratio
$92.30
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.14
$5.80
52 Week High
$5.50
$19.40

Technical Indicators

Market Signals
Indicator
API
TENX
Relative Strength Index (RSI) 52.90 N/A
Support Level $4.01 N/A
Resistance Level $4.16 N/A
Average True Range (ATR) 0.11 0.00
MACD 0.02 0.00
Stochastic Oscillator 98.28 0.00

Price Performance

Historical Comparison
API
TENX

About API Agora Inc.

Agora Inc provides real-time communication solutions. The company offers real-time video calling, voice calling, live audio and video streaming, recording, and real-time messaging. It serves the gaming, retail, and education industries. The company operates in the People's Republic of China and the United States of America and the majority of its revenue is derived from the People's Republic of China.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: